Sign In
Buy ARAY
$0.268
-0.0169 (-5.93%)
At Close: Jul 31, 2026
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
06:26pm, Wednesday, 06'th Nov 2024
Accuray (ARAY) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Accuray Reports Fiscal 2025 First Quarter Financial Results
04:05pm, Wednesday, 06'th Nov 2024
Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis. , Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended Septembe
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
04:05pm, Wednesday, 23'rd Oct 2024
MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference
Accuray Appoints Michael Murphy as VP, Corporate Controller
04:05pm, Monday, 21'st Oct 2024
MADISON, Wis. , Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
12:15pm, Thursday, 17'th Oct 2024
ARAY's solid product demand and revenue growth raise optimism about the stock.
Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence
08:45am, Tuesday, 15'th Oct 2024
MADISON, Wis. , Oct. 15, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced that, effective as of today, Suzanne Winter has returned from her temporary medical leave and assumed her fu
Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
12:51pm, Tuesday, 17'th Sep 2024
ARAY's solid product demand and revenue growth raise optimism about the stock.
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
02:06pm, Monday, 16'th Sep 2024
The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments MADISON, Wis. , Sept. 10, 2024 /PRNewswire/ -- Accuray Incorpo
Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
04:10pm, Tuesday, 03'rd Sep 2024
MADISON, Wis. , Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
01:46pm, Wednesday, 28'th Aug 2024
ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.
Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™
07:35am, Tuesday, 27'th Aug 2024
Developed for India and other countries where patient access to care with radiotherapy is challenged and where versatility and ease of use are a high priority Drives the next phase of company's strate
Accuray Remains A Perpetual 'Next Year Is Our Year' Story
11:55am, Sunday, 18'th Aug 2024
Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
10:41am, Thursday, 15'th Aug 2024
Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.
